Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a probiotic blend melt away liver fat?

NCT ID NCT06537882

Disease control Sponsor: GenieBiome Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a synbiotic supplement called SLP07 can reduce liver fat in people with metabolic dysfunction-associated fatty liver disease. The supplement combines probiotic bacteria, omega 3, and vitamin E. The trial enrolls 54 adults aged 50 and older who have fatty liver disease and signs of metabolic syndrome. Half receive SLP07 and half receive a placebo, and researchers measure changes in liver fat using FibroScan over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a synbiotic blend of probiotics, omega 3, and vitamin E
What this could lead to
If it works, this could offer a low-risk supplement approach to reducing liver fat in people with fatty liver disease.
What could go wrong
This is a small, early study of 54 people, so any benefit may not hold up in larger trials. Supplements can also fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

May 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with MAFLD with CAP ≥ 270 by fibroscan * Age ≥ 50 * Subjects with diabetes or components of metabolic syndrome * Subjects have been taking stable medication 3 months prior to enrolment and are expected to remain stable throughout the study period * Written informed consent can be obtained Exclusion Criteria: * Known history of any secondary causes of MAFLD including alcoholic liver disease, drug-induced liver injury, autoimmune hepatitis, viral hepatitis, cholestatic liver disease and metabolic/genetic liver disease * Active malignancy (on any kind of treatments for the known cancer) * Known diabetes with poor control (HbA1c \> 8.5%) within 3 months * Significant alcohol consumption (over 10g per day: a half pint or half bottle of beer or a standard-size wine glass) * Subjects who are using insulin and Glucagon-like peptide-1(GLP1) such as dulaglutide, semaglutide * Consumption of systemic corticosteroids or methotrexate in the last 6 months * Use of antibiotics, probiotics or prebiotics one month prior to enrolment * Taking any supplements which are claimed to possibly protect the liver or improve liver functions including vitamin E and omega-3 * Any condition or allergy history for probiotics * Any allergy to vitamin E, omega-3 or lactose

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated fatty liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated fatty liver disease

Contacts and locations

Locations

  • GenieBiome Limited

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.